Abstract
Three groups of 40 patients each entered this prospective randomized trial. Patients of group A received 2 ml/kg body weight CMV-Polyglobulin, patients of group B 15 g Intraglobin and patients of group C, serving as controls, received no specific anti-CMV prophylaxis. All patients were given the same sequential immunosuppressive therapy. Patient survival and graft function did not show any significant differences at 2 years follow up. The incidence of fever, CMV infections, dialysis and steroid bolus therapy were lower in group A, but without statistical significance. Patients receiving a graft from a CMV-AK-positive donor were at high risk of developing an infection or reactivation of CMV. A study examining this subgroup seems appropriate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stippel, D., Wienand, P., Weißenberg, N., Baldamus, C., Kruppenbacher, U. (1992). CMV prophylaxis after renal transplantation with immunoglobulin or CMV-hyperimmunoglobulin — a prospective clinical trial. In: Kootstra, G., Opelz, G., Buurman, W.A., van Hooff, J.P., MacMaster, P., Wallwork, J. (eds) Transplant International Official Journal of the European Society for Organ Transplantation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77423-2_46
Download citation
DOI: https://doi.org/10.1007/978-3-642-77423-2_46
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-55342-7
Online ISBN: 978-3-642-77423-2
eBook Packages: Springer Book Archive